// App-Quantinova.ai

9514 : Phase II study of ceralasertib (AZD6738), in combination with durvalumab in patients with metastatic melanoma who have failed prior anti-PD-1 therapy.

Researchers

Presenter

  • Minsuk Kwon

Principal Investigators

  • Seung Tae Kim

  • Simon Smith

  • Claire Smith

  • Peter G. Mortimer

  • Bienvenu LoembE

  • Iwanka Kozarewa

  • Emma Dean

  • Jeeyun Lee

Medical Centers

  • Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

  • Early Oncology Clinical Science, R&D Oncology, AstraZeneca, Cambridge, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Melanoma

Biomarkers

  • N/A

Drug/Treatment

  • Durvalumab

  • AZD6738

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT03780608

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved